Placebo-Controlled, 52 week Study to assess the efficacy and safety of Etrasimod in subjects with moderately to severely active UC.
- Etrasimod is an orally administered, selective, synthetic sphingosine 1-pjhospahte receptor (SIP)
- Males and females 16-80 with a diagnosis of moderately to severely active UC.
- Must have failed or had inadequate response to: 5-ASAs. Steroids, biologics or JAK 1s.
- Open-label extension following end of study
If you are interested in participating in clinical studies, please send an email to email@example.com.